Produktname:2,6-Dichloro-5-fluoronicotinamide
IUPAC Name:2,6-dichloro-5-fluoropyridine-3-carboxamide
- CAS：113237-20-0
- Molekulare Formel：C6H3Cl2FN2O
- Reinheit：98%
- Katalognummer：CM178393
- Molekulargewicht：209
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:113237-20-0
- Molekulare Formel:C6H3Cl2FN2O
- Schmelzpunkt:-
- SMILES-Code:O=C(N)C1=C(Cl)N=C(Cl)C(F)=C1
- Dichte:
- Katalognummer:CM178393
- Molekulargewicht:209
- Siedepunkt:
- Mdl-Nr.:MFCD01571365
- Lagerung:Store at room temperature
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Sotorasib
- Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.
Suche 
+86 21 5895 0110 
